Abstract: A new polymorphic form of (R)-praziquantel is provided, the novel anhydrate (R)-2-(cyclohexanecarbonyl)-2,3,6,7-tetrahydro-1h-pyrazino[2,1-a]isoquinolin-4(11bh)-one, compositions including the polymorphic form, methods of making pharmaceutical formulations including the polymorphic form. Improved methods of their use for controlling, treating and preventing zoonotic and parasitic diseases in humans and animals is also provided, which includes administering to the subject in need thereof a therapeutically effective amount of the active agent with a pharmaceutical formulation.

Abstract: Provided are compositions relating to novel MDR1 polymorphisms, including nucleic acids, polypeptides, and recombinant cells, as well as methods for detection of MDR1 polymorphisms in biological samples and elucidation of the influence of MDR1 polymorphisms on MDR1 protein function. Also provided are a rat MRP1 cDNA and protein, stable cell lines expressing the rat MRP1 protein, and methods of assessing drug penetration or disposition in a cell line expressing a recombinant mammalian MRP1 or MDR1 protein, or a homolog thereof.

Abstract: A method for preventing or ameliorating HSV infection in a bird or mammal comprises administering a composition comprising an effective amount of an HSV surface glycoprotein and an effective amount of an MDP equivalent, encapsulated in liposomes. The resulting composition is useful for reducing the severity and recurrence of HSV outbreaks.